Search

everythinglearnresearchcommunity

for

Search:↓

A humorous discussion about hair loss treatments, specifically mentioning the use of 5mg of Dutasteride. The conversation includes jokes about the effectiveness of the treatment.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The conversation is about hair loss treatments, specifically a stack including topical Ashwagandha, Copper Peptide, Gotu Kola, Ketoconazole, and PDA. One user found Topical and Sub-Q GHK-CU effective.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

The user had a hair transplant with 4500 grafts and has been using minoxidil twice daily for over a year but stopped finasteride due to severe side effects. The transplant cost $3500 and improved their self-confidence, positively affecting their dating life.

Significant hair regrowth was achieved over six months using minoxidil, finasteride, microneedling, biotin and collagen shampoo, and MSM powder. The user feels more confident and may consider a hair transplant if necessary.

The user shared progress photos of hair regrowth using copper peptides and NAD+ over five months. Another user commented on the lighting, and another praised the progress.

A 36-year-old male using dutasteride and minoxidil has seen significant hair regrowth, confirmed by a dermatologist and supported by before-and-after photos. He plans to increase his oral minoxidil dosage and add dermapen to his routine.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.

A female user with alopecia is researching peptide usage, specifically ghk-cu, for hair loss. Other users shared mixed experiences with copper treatments, noting some success with topical application.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

The user stopped using finasteride after two weeks due to gynecomastia symptoms and shared blood work results questioning if they indicate a cause for the side effects. The user is considering restarting finasteride and seeking advice on their blood work levels in relation to gynecomastia.

The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

The user is very satisfied with their hair transplant results after six months, using finasteride, minoxidil, and ketoconazole shampoo. They praise Dr. Anuj and consider future touch-ups for a small untouched crown area.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

A 40-year-old shared their positive experience with a second hair transplant at HDC Cyprus, involving 4148 grafts and costing around 9,000 euros. They used oral minoxidil, Dutasteride, biotin, and vitamins to aid recovery and were pleased with the results.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.